Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes
The incidence of diabetes and its association with increased cardiovascular disease risk represents a major health issue worldwide. Diabetes-induced hyperglycemia is implicated as a central driver of responses in the diabetic heart such as cardiomyocyte hypertrophy, fibrosis, and oxidative stress, t...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphys.2020.00124/full |
id |
doaj-ad0834e4ceeb441888ccbf644f35fb0c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Miles J. De Blasio Miles J. De Blasio Nguyen Huynh Nguyen Huynh Minh Deo Leslie E. Dubrana Jesse Walsh Andrew Willis Darnel Prakoso Darnel Prakoso Helen Kiriazis Daniel G. Donner John C. Chatham Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie |
spellingShingle |
Miles J. De Blasio Miles J. De Blasio Nguyen Huynh Nguyen Huynh Minh Deo Leslie E. Dubrana Jesse Walsh Andrew Willis Darnel Prakoso Darnel Prakoso Helen Kiriazis Daniel G. Donner John C. Chatham Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes Frontiers in Physiology type 1 diabetes diabetic cardiomyopathy cardiomyocyte hypertrophy cardiac fibrosis diastolic dysfunction |
author_facet |
Miles J. De Blasio Miles J. De Blasio Nguyen Huynh Nguyen Huynh Minh Deo Leslie E. Dubrana Jesse Walsh Andrew Willis Darnel Prakoso Darnel Prakoso Helen Kiriazis Daniel G. Donner John C. Chatham Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie Rebecca H. Ritchie |
author_sort |
Miles J. De Blasio |
title |
Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes |
title_short |
Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes |
title_full |
Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes |
title_fullStr |
Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes |
title_full_unstemmed |
Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 Diabetes |
title_sort |
defining the progression of diabetic cardiomyopathy in a mouse model of type 1 diabetes |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Physiology |
issn |
1664-042X |
publishDate |
2020-02-01 |
description |
The incidence of diabetes and its association with increased cardiovascular disease risk represents a major health issue worldwide. Diabetes-induced hyperglycemia is implicated as a central driver of responses in the diabetic heart such as cardiomyocyte hypertrophy, fibrosis, and oxidative stress, termed diabetic cardiomyopathy. The onset of these responses in the setting of diabetes has not been studied to date. This study aimed to determine the time course of development of diabetic cardiomyopathy in a model of type 1 diabetes (T1D) in vivo. Diabetes was induced in 6-week-old male FVB/N mice via streptozotocin (55 mg/kg i.p. for 5 days; controls received citrate vehicle). At 2, 4, 8, 12, and 16 weeks of untreated diabetes, left ventricular (LV) function was assessed by echocardiography before post-mortem quantification of markers of LV cardiomyocyte hypertrophy, collagen deposition, DNA fragmentation, and changes in components of the hexosamine biosynthesis pathway (HBP) were assessed. Blood glucose and HbA1c levels were elevated by 2 weeks of diabetes. LV and muscle (gastrocnemius) weights were reduced from 8 weeks, whereas liver and kidney weights were increased from 2 and 4 weeks of diabetes, respectively. LV diastolic function declined with diabetes progression, demonstrated by a reduction in E/A ratio from 4 weeks of diabetes, and an increase in peak A-wave amplitude, deceleration time, and isovolumic relaxation time (IVRT) from 4–8 weeks of diabetes. Systemic and local inflammation (TNFα, IL-1β, CD68) were increased with diabetes. The cardiomyocyte hypertrophic marker Nppa was increased from 8 weeks of diabetes while β-myosin heavy chain was increased earlier, from 2 weeks of diabetes. LV fibrosis (picrosirius red; Ctgf and Tgf-β gene expression) and DNA fragmentation (a marker of cardiomyocyte apoptosis) increased with diabetes progression. LV Nox2 and Cd36 expression were elevated after 16 weeks of diabetes. Markers of the LV HBP (Ogt, Oga, Gfat1/2 gene expression), and protein abundance of OGT and total O-GlcNAcylation, were increased by 16 weeks of diabetes. This is the first study to define the progression of cardiac markers contributing to the development of diabetic cardiomyopathy in a mouse model of T1D, confirming multiple pathways contribute to disease progression at various time points. |
topic |
type 1 diabetes diabetic cardiomyopathy cardiomyocyte hypertrophy cardiac fibrosis diastolic dysfunction |
url |
https://www.frontiersin.org/article/10.3389/fphys.2020.00124/full |
work_keys_str_mv |
AT milesjdeblasio definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT milesjdeblasio definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT nguyenhuynh definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT nguyenhuynh definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT minhdeo definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT leslieedubrana definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT jessewalsh definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT andrewwillis definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT darnelprakoso definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT darnelprakoso definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT helenkiriazis definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT danielgdonner definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT johncchatham definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT rebeccahritchie definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT rebeccahritchie definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT rebeccahritchie definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes AT rebeccahritchie definingtheprogressionofdiabeticcardiomyopathyinamousemodeloftype1diabetes |
_version_ |
1724730506224861184 |
spelling |
doaj-ad0834e4ceeb441888ccbf644f35fb0c2020-11-25T02:52:21ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2020-02-011110.3389/fphys.2020.00124507301Defining the Progression of Diabetic Cardiomyopathy in a Mouse Model of Type 1 DiabetesMiles J. De Blasio0Miles J. De Blasio1Nguyen Huynh2Nguyen Huynh3Minh Deo4Leslie E. Dubrana5Jesse Walsh6Andrew Willis7Darnel Prakoso8Darnel Prakoso9Helen Kiriazis10Daniel G. Donner11John C. Chatham12Rebecca H. Ritchie13Rebecca H. Ritchie14Rebecca H. Ritchie15Rebecca H. Ritchie16Heart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaSchool of BioSciences, The University of Melbourne, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaDepartment of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaSchool of BioSciences, The University of Melbourne, Melbourne, VIC, AustraliaExperimental Cardiology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaExperimental Cardiology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL, United StatesHeart Failure Pharmacology, Baker Heart and Diabetes Institute, Melbourne, VIC, AustraliaDepartment of Pharmacology and Therapeutics, The University of Melbourne, Melbourne, VIC, AustraliaDepartment of Medicine, Monash University, Melbourne, VIC, AustraliaDepartment of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, AustraliaThe incidence of diabetes and its association with increased cardiovascular disease risk represents a major health issue worldwide. Diabetes-induced hyperglycemia is implicated as a central driver of responses in the diabetic heart such as cardiomyocyte hypertrophy, fibrosis, and oxidative stress, termed diabetic cardiomyopathy. The onset of these responses in the setting of diabetes has not been studied to date. This study aimed to determine the time course of development of diabetic cardiomyopathy in a model of type 1 diabetes (T1D) in vivo. Diabetes was induced in 6-week-old male FVB/N mice via streptozotocin (55 mg/kg i.p. for 5 days; controls received citrate vehicle). At 2, 4, 8, 12, and 16 weeks of untreated diabetes, left ventricular (LV) function was assessed by echocardiography before post-mortem quantification of markers of LV cardiomyocyte hypertrophy, collagen deposition, DNA fragmentation, and changes in components of the hexosamine biosynthesis pathway (HBP) were assessed. Blood glucose and HbA1c levels were elevated by 2 weeks of diabetes. LV and muscle (gastrocnemius) weights were reduced from 8 weeks, whereas liver and kidney weights were increased from 2 and 4 weeks of diabetes, respectively. LV diastolic function declined with diabetes progression, demonstrated by a reduction in E/A ratio from 4 weeks of diabetes, and an increase in peak A-wave amplitude, deceleration time, and isovolumic relaxation time (IVRT) from 4–8 weeks of diabetes. Systemic and local inflammation (TNFα, IL-1β, CD68) were increased with diabetes. The cardiomyocyte hypertrophic marker Nppa was increased from 8 weeks of diabetes while β-myosin heavy chain was increased earlier, from 2 weeks of diabetes. LV fibrosis (picrosirius red; Ctgf and Tgf-β gene expression) and DNA fragmentation (a marker of cardiomyocyte apoptosis) increased with diabetes progression. LV Nox2 and Cd36 expression were elevated after 16 weeks of diabetes. Markers of the LV HBP (Ogt, Oga, Gfat1/2 gene expression), and protein abundance of OGT and total O-GlcNAcylation, were increased by 16 weeks of diabetes. This is the first study to define the progression of cardiac markers contributing to the development of diabetic cardiomyopathy in a mouse model of T1D, confirming multiple pathways contribute to disease progression at various time points.https://www.frontiersin.org/article/10.3389/fphys.2020.00124/fulltype 1 diabetesdiabetic cardiomyopathycardiomyocyte hypertrophycardiac fibrosisdiastolic dysfunction |